← The library
Thymosin Beta-4 (Tβ4)
Healing/RecoveryEvidence grade
CMixed/unclear regulatory status
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeHealing / Immune
MechanismActin-binding peptide involved in wound healing and inflammation modulation
EffectsActin-binding peptide involved in wound healing and inflammation modulation
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialPhase 1 IV safety study (healthy volunteers)
RouteIntravenous
FrequencySingle dose, then daily for 14 days
StartingSingle ascending doses: 42, 140, 420 or 1260 mg
EscalationSame dose daily for 14 days
TargetSafety study only; no dose-limiting toxicity
Safety-finding doses, not efficacy doses, and not a regimen for subcutaneous use.
SourcePubMed 20536472 ↗
Clinical trialRGN-259 eye drops (neurotrophic keratopathy / dry eye)
RouteTopical ophthalmic, 0.1% solution
Frequency5 times/day (neurotrophic keratopathy); twice daily (dry eye)
Starting0.1% RGN-259
EscalationNone
Target5 times/day for 4 weeks (NK, n=18); twice daily for 28 days (dry eye)
Batches on filenone
No tested batches on file.
Cautions & interactions
Not FDA-approved for this use; unknown risks
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.